Tempus AI acquires Paige to accelerate oncology AI innovation
CHICAGO: Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence-driven precision medicine, announced Friday it has acquired Paige, a digital pathology company known for pioneering FDA-cleared AI applications in cancer detection. The $81.25 million deal, primarily paid in Tempus…